CovidChloroV1, Main, Exploration, bibRecord, 001851

Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.

Identifieur interne : 001851 ( Main/Exploration ); précédent : 001850; suivant : 001852

Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.

Auteurs : Janet Sultana [Italie] ; Paola Maria Cutroneo [Italie] ; Salvatore Crisafulli [Italie] ; Gabriele Puglisi [Italie] ; Gaetano Caramori [Italie] ; Gianluca Trifir [Italie]

Source :

Drug safety [ 1179-1942 ] ; 2020.

RBID : pubmed:32696429

Descripteurs français

KwdFr :
- Antibactériens (pharmacologie), Azithromycine (pharmacologie), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (physiologie), Co-infection (diagnostic), Co-infection (traitement médicamenteux), Gestion de la pharmacothérapie (normes), Guides de bonnes pratiques cliniques comme sujet (MeSH), Humains (MeSH), Infections à coronavirus (immunologie), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Pandémies (MeSH), Pneumopathie virale (immunologie), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Résultat thérapeutique (MeSH), Sélection de patients (MeSH).
MESH :
- diagnostic : Co-infection.
- effets des médicaments et des substances chimiques : Betacoronavirus.
- immunologie : Infections à coronavirus, Pneumopathie virale.
- normes : Gestion de la pharmacothérapie.
- pharmacologie : Antibactériens, Azithromycine.
- physiologie : Betacoronavirus.
- traitement médicamenteux : Co-infection, Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Guides de bonnes pratiques cliniques comme sujet, Humains, Pandémies, Résultat thérapeutique, Sélection de patients.

English descriptors

KwdEn :
- Anti-Bacterial Agents (pharmacology), Azithromycin (pharmacology), Betacoronavirus (drug effects), Betacoronavirus (physiology), COVID-19 (MeSH), Coinfection (diagnosis), Coinfection (drug therapy), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (immunology), Humans (MeSH), Medication Therapy Management (standards), Pandemics (MeSH), Patient Selection (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Pneumonia, Viral (immunology), Practice Guidelines as Topic (MeSH), SARS-CoV-2 (MeSH), Treatment Outcome (MeSH).
MESH :
- chemical , pharmacology : Anti-Bacterial Agents, Azithromycin.
- diagnosis : Coinfection.
- drug effects : Betacoronavirus.
- drug therapy : Coinfection, Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- immunology : Coronavirus Infections, Pneumonia, Viral.
- physiology : Betacoronavirus.
- standards : Medication Therapy Management.
- COVID-19, Humans, Pandemics, Patient Selection, Practice Guidelines as Topic, SARS-CoV-2, Treatment Outcome.

Abstract

The global COVID-19 pandemic has led to a race to find medications that can improve the prognosis of the disease. Azithromycin, in association with hydroxychloroquine or chloroquine, has been proposed as one such medication. The aim of this review is to describe the pharmacological mechanism, clinical evidence and prescribing guidelines concerning azithromycin in COVID-19 patients. There is weak evidence on the antiviral and immunomodulating effects of azithromycin, which in addition is not based on results from COVID-19 patients specifically. Therefore, this antibacterial should be considered only as empirical treatment of community-acquired pneumonia (CAP), although not all current treatment guidelines are in agreement. After the initial expectations raised by a small trial, more recent evidence has raised serious safety concerns on the use of hydroxychloroquine or chloroquine with azithromycin to treat COVID-19 patients, as all these drugs have arrhythmogenic potential. The World Health Organization has not made recommendations suggesting the use of azithromycin with hydroxychloroquine or chloroquine as treatment for COVID-19, but some national organisations have taken a different position, recommending this as first-line treatment. Several scientific societies, including the American College of Cardiology, have cautioned about the risks of this treatment in view of the lack of evidence concerning its benefits.

DOI: 10.1007/s40264-020-00976-7
PubMed: 32696429
PubMed Central: PMC7371963

Affiliations:

Italie

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001081
to stream Main, to step Curation: 001081

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.</title>
<author><name sortKey="Sultana, Janet" sort="Sultana, Janet" uniqKey="Sultana J" first="Janet" last="Sultana">Janet Sultana</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina</wicri:regionArea>
<wicri:noRegion>Messina</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cutroneo, Paola Maria" sort="Cutroneo, Paola Maria" uniqKey="Cutroneo P" first="Paola Maria" last="Cutroneo">Paola Maria Cutroneo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina</wicri:regionArea>
<wicri:noRegion>Messina</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Crisafulli, Salvatore" sort="Crisafulli, Salvatore" uniqKey="Crisafulli S" first="Salvatore" last="Crisafulli">Salvatore Crisafulli</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina</wicri:regionArea>
<wicri:noRegion>Messina</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Puglisi, Gabriele" sort="Puglisi, Gabriele" uniqKey="Puglisi G" first="Gabriele" last="Puglisi">Gabriele Puglisi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina</wicri:regionArea>
<wicri:noRegion>Messina</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Caramori, Gaetano" sort="Caramori, Gaetano" uniqKey="Caramori G" first="Gaetano" last="Caramori">Gaetano Caramori</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina</wicri:regionArea>
<wicri:noRegion>Messina</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Trifir, Gianluca" sort="Trifir, Gianluca" uniqKey="Trifir G" first="Gianluca" last="Trifir">Gianluca Trifir</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy. trifirog@unime.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina</wicri:regionArea>
<wicri:noRegion>Messina</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32696429</idno>
<idno type="pmid">32696429</idno>
<idno type="doi">10.1007/s40264-020-00976-7</idno>
<idno type="pmc">PMC7371963</idno>
<idno type="wicri:Area/Main/Corpus">001081</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001081</idno>
<idno type="wicri:Area/Main/Curation">001081</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001081</idno>
<idno type="wicri:Area/Main/Exploration">001081</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.</title>
<author><name sortKey="Sultana, Janet" sort="Sultana, Janet" uniqKey="Sultana J" first="Janet" last="Sultana">Janet Sultana</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina</wicri:regionArea>
<wicri:noRegion>Messina</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cutroneo, Paola Maria" sort="Cutroneo, Paola Maria" uniqKey="Cutroneo P" first="Paola Maria" last="Cutroneo">Paola Maria Cutroneo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina</wicri:regionArea>
<wicri:noRegion>Messina</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Crisafulli, Salvatore" sort="Crisafulli, Salvatore" uniqKey="Crisafulli S" first="Salvatore" last="Crisafulli">Salvatore Crisafulli</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina</wicri:regionArea>
<wicri:noRegion>Messina</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Puglisi, Gabriele" sort="Puglisi, Gabriele" uniqKey="Puglisi G" first="Gabriele" last="Puglisi">Gabriele Puglisi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina</wicri:regionArea>
<wicri:noRegion>Messina</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Caramori, Gaetano" sort="Caramori, Gaetano" uniqKey="Caramori G" first="Gaetano" last="Caramori">Gaetano Caramori</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina</wicri:regionArea>
<wicri:noRegion>Messina</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Trifir, Gianluca" sort="Trifir, Gianluca" uniqKey="Trifir G" first="Gianluca" last="Trifir">Gianluca Trifir</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy. trifirog@unime.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina</wicri:regionArea>
<wicri:noRegion>Messina</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Drug safety</title>
<idno type="eISSN">1179-1942</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Bacterial Agents (pharmacology)</term>
<term>Azithromycin (pharmacology)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (physiology)</term>
<term>COVID-19 (MeSH)</term>
<term>Coinfection (diagnosis)</term>
<term>Coinfection (drug therapy)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Humans (MeSH)</term>
<term>Medication Therapy Management (standards)</term>
<term>Pandemics (MeSH)</term>
<term>Patient Selection (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (immunology)</term>
<term>Practice Guidelines as Topic (MeSH)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antibactériens (pharmacologie)</term>
<term>Azithromycine (pharmacologie)</term>
<term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Betacoronavirus (physiologie)</term>
<term>Co-infection (diagnostic)</term>
<term>Co-infection (traitement médicamenteux)</term>
<term>Gestion de la pharmacothérapie (normes)</term>
<term>Guides de bonnes pratiques cliniques comme sujet (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (immunologie)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Sélection de patients (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Azithromycin</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coinfection</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Co-infection</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coinfection</term>
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Gestion de la pharmacothérapie</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antibactériens</term>
<term>Azithromycine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Medication Therapy Management</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Co-infection</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Humans</term>
<term>Pandemics</term>
<term>Patient Selection</term>
<term>Practice Guidelines as Topic</term>
<term>SARS-CoV-2</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Guides de bonnes pratiques cliniques comme sujet</term>
<term>Humains</term>
<term>Pandémies</term>
<term>Résultat thérapeutique</term>
<term>Sélection de patients</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The global COVID-19 pandemic has led to a race to find medications that can improve the prognosis of the disease. Azithromycin, in association with hydroxychloroquine or chloroquine, has been proposed as one such medication. The aim of this review is to describe the pharmacological mechanism, clinical evidence and prescribing guidelines concerning azithromycin in COVID-19 patients. There is weak evidence on the antiviral and immunomodulating effects of azithromycin, which in addition is not based on results from COVID-19 patients specifically. Therefore, this antibacterial should be considered only as empirical treatment of community-acquired pneumonia (CAP), although not all current treatment guidelines are in agreement. After the initial expectations raised by a small trial, more recent evidence has raised serious safety concerns on the use of hydroxychloroquine or chloroquine with azithromycin to treat COVID-19 patients, as all these drugs have arrhythmogenic potential. The World Health Organization has not made recommendations suggesting the use of azithromycin with hydroxychloroquine or chloroquine as treatment for COVID-19, but some national organisations have taken a different position, recommending this as first-line treatment. Several scientific societies, including the American College of Cardiology, have cautioned about the risks of this treatment in view of the lack of evidence concerning its benefits.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32696429</PMID>
<DateCompleted><Year>2020</Year>
<Month>08</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>43</Volume>
<Issue>8</Issue>
<PubDate><Year>2020</Year>
<Month>08</Month>
</PubDate>
</JournalIssue>
<Title>Drug safety</Title>
<ISOAbbreviation>Drug Saf</ISOAbbreviation>
</Journal>
<ArticleTitle>Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.</ArticleTitle>
<Pagination><MedlinePgn>691-698</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-020-00976-7</ELocationID>
<Abstract><AbstractText>The global COVID-19 pandemic has led to a race to find medications that can improve the prognosis of the disease. Azithromycin, in association with hydroxychloroquine or chloroquine, has been proposed as one such medication. The aim of this review is to describe the pharmacological mechanism, clinical evidence and prescribing guidelines concerning azithromycin in COVID-19 patients. There is weak evidence on the antiviral and immunomodulating effects of azithromycin, which in addition is not based on results from COVID-19 patients specifically. Therefore, this antibacterial should be considered only as empirical treatment of community-acquired pneumonia (CAP), although not all current treatment guidelines are in agreement. After the initial expectations raised by a small trial, more recent evidence has raised serious safety concerns on the use of hydroxychloroquine or chloroquine with azithromycin to treat COVID-19 patients, as all these drugs have arrhythmogenic potential. The World Health Organization has not made recommendations suggesting the use of azithromycin with hydroxychloroquine or chloroquine as treatment for COVID-19, but some national organisations have taken a different position, recommending this as first-line treatment. Several scientific societies, including the American College of Cardiology, have cautioned about the risks of this treatment in view of the lack of evidence concerning its benefits.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sultana</LastName>
<ForeName>Janet</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cutroneo</LastName>
<ForeName>Paola Maria</ForeName>
<Initials>PM</Initials>
<AffiliationInfo><Affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Crisafulli</LastName>
<ForeName>Salvatore</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Puglisi</LastName>
<ForeName>Gabriele</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Caramori</LastName>
<ForeName>Gaetano</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Trifirò</LastName>
<ForeName>Gianluca</ForeName>
<Initials>G</Initials>
<Identifier Source="ORCID">0000-0003-1147-7296</Identifier>
<AffiliationInfo><Affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy. trifirog@unime.it.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>New Zealand</Country>
<MedlineTA>Drug Saf</MedlineTA>
<NlmUniqueID>9002928</NlmUniqueID>
<ISSNLinking>0114-5916</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D060085" MajorTopicYN="Y">Coinfection</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054539" MajorTopicYN="N">Medication Therapy Management</DescriptorName>
<QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>7</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>7</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32696429</ArticleId>
<ArticleId IdType="doi">10.1007/s40264-020-00976-7</ArticleId>
<ArticleId IdType="pii">10.1007/s40264-020-00976-7</ArticleId>
<ArticleId IdType="pmc">PMC7371963</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):14408-14413</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27911847</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 May 17;366(20):1881-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22591294</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Mar 14;9(3):e91293</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24632748</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Pharmacol. 2006 Dec;149(8):1039-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17088870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Infect Dis. 2015 Jul 10;1(7):317-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27622822</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2019 Apr;81:184-190</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30690213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2014 Jun 4;311(21):2199-208</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24893087</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Cardiol. 2020 Oct 1;316:280-284</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32439366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ Arrhythm Electrophysiol. 2017 Apr;10(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28408648</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Clin (Barc). 2001 Jun 23;117(3):118-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11459586</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2006 Dec 15;43(12):1603-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17109296</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anesth Analg. 1997 Nov;85(5):1011-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9356092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Biomed. 2006 Apr;77(1):30-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16856707</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pacing Clin Electrophysiol. 2001 Oct;24(10):1572-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11707055</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mayo Clin Proc. 2020 Jun;95(6):1213-1221</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32359771</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2010 Sep;36(3):646-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20150207</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>CMAJ. 2016 Apr 19;188(7):E120-E129</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26903359</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Ther. 2014 Aug;143(2):225-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24631273</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Pharmacol. 2000 Apr;56(1):1-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10853872</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32347743</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Z Med J. 2003 Nov 07;116(1185):U666</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14615808</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Interv Card Electrophysiol. 2007 Apr;18(3):243-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17546486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am Health Drug Benefits. 2014 Sep;7(6):318-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25558301</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Therapie. 2020 Jul - Aug;75(4):371-379</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32418730</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Fam Med. 2014 Mar-Apr;12(2):121-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24615307</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2013 May 2;368(18):1704-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23635050</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2015 Feb 15;60(4):566-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25409476</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Jun 23;323(24):2493-2502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32392282</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 1998 Nov 25;280(20):1774-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9842954</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Trop Med Hyg. 2007 Nov;77(5):929-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17984356</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Cardiol. 1988 Jan 1;61(1):8-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3337021</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Postgrad Med. 2017 Jun;129(5):493-499</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28116959</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Health Syst Pharm. 2007 Apr 15;64(8):830-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17420199</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pacing Clin Electrophysiol. 2005 Nov;28(11):1221-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16359290</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacotherapy. 1996 Jul-Aug;16(4):663-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8840374</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>CMAJ. 2017 Apr 18;189(15):E560-E568</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28420680</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharmacol Exp Ther. 2002 Oct;303(1):218-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12235254</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Rev. 2010 Jul;23(3):590-615</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20610825</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2016 May 18;11(5):e0155649</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27192430</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2014 Oct 09;(10):CD002109</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25300166</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2002 Jul 15;35(2):197-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12087527</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pacing Clin Electrophysiol. 2007 Dec;30(12):1579-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18070319</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 May 19;323(19):1895-1896</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32227198</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jul 17;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32678530</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Cardiol. 2020 Sep 1;5(9):1036-1041</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32936252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Saf. 2010 Apr 1;33(4):303-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20297862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Heart Assoc. 2018 Apr 21;7(9):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29680825</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2005 Apr 21;352(16):1637-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15843666</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2020 Aug 18;173(4):304-305</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32379883</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pacing Clin Electrophysiol. 2001 Oct;24(10):1575-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11707056</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32242738</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 Jun;26(6):808-809</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32488217</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 1982 Mar;65(3):457-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7055867</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Italie</li>
</country>
</list>
<tree><country name="Italie"><noRegion><name sortKey="Sultana, Janet" sort="Sultana, Janet" uniqKey="Sultana J" first="Janet" last="Sultana">Janet Sultana</name>
</noRegion>
<name sortKey="Caramori, Gaetano" sort="Caramori, Gaetano" uniqKey="Caramori G" first="Gaetano" last="Caramori">Gaetano Caramori</name>
<name sortKey="Crisafulli, Salvatore" sort="Crisafulli, Salvatore" uniqKey="Crisafulli S" first="Salvatore" last="Crisafulli">Salvatore Crisafulli</name>
<name sortKey="Cutroneo, Paola Maria" sort="Cutroneo, Paola Maria" uniqKey="Cutroneo P" first="Paola Maria" last="Cutroneo">Paola Maria Cutroneo</name>
<name sortKey="Puglisi, Gabriele" sort="Puglisi, Gabriele" uniqKey="Puglisi G" first="Gabriele" last="Puglisi">Gabriele Puglisi</name>
<name sortKey="Trifir, Gianluca" sort="Trifir, Gianluca" uniqKey="Trifir G" first="Gianluca" last="Trifir">Gianluca Trifir</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001851 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001851 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32696429
   |texte=   Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32696429" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.

Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki